Document is current
Any future updates will be listed below
-
Authors
Gallon, Richard
Herrero-Belmonte, Patricia
Phelps, Rachel
Hayes, Christine
Sollars, Elizabeth
Egan, Daniel
Spiewak, Helena
Nalty, Sam
Mills, Sarah
Loo, Peh Sun
Borthwick, Gillian M.
Santibanez-Koref, Mauro
Burn, John
McAnulty, Ciaron
Jackson, Michael S.
-
Funding
Funding for this research was provided by:
Cancer Research UK (C569/A24991)
Cancer Research UK (C569/A24991)
Cancer Research UK (C569/A24991)
NHS England Small Business Research Initiative (SBRIC01P3040)
NHS England Small Business Research Initiative (SBRIC01P3040)
NHS England Small Business Research Initiative (SBRIC01P3040)
NHS England Small Business Research Initiative (SBRIC01P3040)
NHS England Small Business Research Initiative (SBRIC01P3040)
The Barbour Foundation (UK charity 328081)
The Barbour Foundation (UK charity 328081)
The Barbour Foundation (UK charity 328081)
- License Information
-
More Information
Article History
Received: 29 March 2024
Revised: 31 May 2024
Accepted: 9 June 2024
First Online: 1 July 2024
Competing interests
: R. Gallon, J. Burn, M. S. Jackson, and M. Santibanez-Koref are named inventors on patents covering the microsatellite instability markers analysed: WO/2018/037231 (published March 1, 2018), WO/2021/019197 (published February 4, 2021), and GB2114136.1 (filed October 1, 2021). The other authors declare no conflicts of interest.
: Ethical approval for use of excess diagnostic samples during assay development was granted by the NHS Health Research Authority (REC reference 13/LO/1514). Patient consent was obtained for use of excess diagnostic samples for clinical validation of novel assays. Clinical audits were conducted following The Caldicott Principles ().
